Christopher Paul Simms - 25 Mar 2026 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Reporting relationship: Chief Commercial and Business Officer
Issuer ticker: FDMT
Reported as of: 25 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Mar 2026, 16:30:02 UTC
Prior SEC filing: 19 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Scott Bizily as Attorney-in-Fact for Christopher Paul Simms

Key filing fact

Christopher Paul Simms filed Form 4 for 4D Molecular Therapeutics, Inc. (FDMT) on 27 Mar 2026.

Key facts

This page summarizes Christopher Paul Simms's Form 4 filing for 4D Molecular Therapeutics, Inc. (FDMT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 Mar 2026, 16:30.

Change

Previous filing in this sequence was filed on 19 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001877012 Primary reporting owner

Simms Christopher Paul

Relationship: Chief Commercial and Business Officer
Address: C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE
Signature: /s/ Scott Bizily as Attorney-in-Fact for Christopher Paul Simms
Signature date: 27 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FDMT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +219,000
Change %
Price: $0.000000^*
Shares after: 219,000
Date: 25 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 219,000
Exercise price: $9.88
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 25, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

SEC remarks

Chief Commercial and Business Officer